A Phase 3 interventional study of Obinutuzumab and Ublituximab in Chronic Lymphocytic Leukemia, sponsored by TG Therapeutics, Inc.. Terminated at 154 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-12-13.
Sponsored by TG Therapeutics, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell — none open to participants now, 1 under way, none of them phase 3. ublituximab · Leukemia, Lymphocytic, Chronic, B-Cell.
Among the 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell, this one has the largest enrollment, is one of 2 that started in 2015, is one of 2 in phase 3, and was the 7th registered.
2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.
Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →None of the 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell is open now. The open studies under Leukemia, Lymphocytic, Chronic, B-Cell, anywhere →
ublituximab: first FDA approval 2022 (BRIUMVI), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →
Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 8 · Phase 3 3
First in 2008; this study’s year is marked. 2 started in 2015.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 603 is above the median of 39 across 1,603 interventional studies indexed under Leukemia, Lymphocytic, Chronic, B-Cell.
Median enrollment 51 across the 13 interventional studies. Of the 12 that completed or were terminated, 6 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 13 have an industry lead sponsor. The 4 most frequent:
TG Therapeutics, Inc. is the lead sponsor of 40 studies on the registry; 9 are open to participants now.
Of its 16 completed or terminated interventional studies of FDA-regulated products, 9 (56%) have results posted.
18 studies in Leukemia, Lymphocytic, Chronic, B-Cell by TG Therapeutics, Inc.: none open now, none under way, none of them phase 3. Of 18 finished, 7 (39%) have results posted.
Among the 18 studies in Leukemia, Lymphocytic, Chronic, B-Cell by TG Therapeutics, Inc., this one is the 2nd largest by enrollment, is one of 3 that started in 2015, is one of 2 in phase 3, and was the 9th registered.
TG Therapeutics, Inc.’s Leukemia, Lymphocytic, Chronic, B-Cell studies by the year they started, since 2012.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among TG Therapeutics, Inc.’s 18 in Leukemia, Lymphocytic, Chronic, B-Cell:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study evaluates the combination of ublituximab, a novel monoclonal antibody, and TGR-1202, a novel PI3K delta inhibitor compared to obinutuzumab and chlorambucil, and compared to ublituximab or TGR-1202 alone in Chronic Lymphocytic Leukemia (CLL) participants.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received ublituximab, 150 milligrams (mg), intravenously (IV), on Day 1, 750 mg on Day 2, followed by 900 mg on Days 8 and 15 of Cycle 1 (cycle length=28 days), Day 1 of Cycles 2-6, and once every 3 cycles thereafter, along with umbralisib, 800 mg, orally, once daily during each cycle until disease progression, lack of tolerability, or until the treatment is commercially available or up to 87 months.
Biological: Ublituximab · Drug: TGR-1202
Participants received Obinutuzumab 100 mg, IV on Day 1, 900 mg on Day 2, followed by 1000 mg on Days 8 and 15 of cycle 1 (cycle length = 28 days), Day 1 of Cycle 2-6 along with Chlorambucil 0.5 milligram per kilogram (mg/kg) tablet orally on Days 1 and 15 once daily during each cycle until disease progression, lack of tolerability, or until the treatment is commercially available or up to 87 months.
Biological: Obinutuzumab · Drug: Chlorambucil
Participants received ublituximab, 150 mg, IV, on Day 1, 750 mg on Day 2, followed by 900 mg on Days 8 and 15 of Cycle 1 (cycle length=28 days), Day 1 of Cycles 2-6, and once every 3 cycles thereafter, until disease progression, lack of tolerability, or until the treatment is commercially available or up to 87 months.
Biological: Ublituximab
Participants received umbralisib, 800 mg tablets, orally, once daily during each cycle (cycle length= 28 days) until removal from study or up to 87 months.
Drug: TGR-1202
Obinutuzumab: IV infusion
Also known as: GAZYVA
Ublituximab: IV infusion
TGR-1202: Oral daily dose
Chlorambucil: Oral dose
Also known as: Leukeran
Progression-Free Survival (PFS) Per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria
PFS was defined as the interval from enrollment to the earlier of the first documentation of definitive disease progression (PD) or death from any cause. PD was appearance of new nodes \>1.5 centimetres (cm) in the longest diameter (LD) and \>1.0 in longest perpendicular diameter (LPD), new or recurrent hepatomegaly or splenomegaly, new or reappearance of an unequivocal extra-nodal lesion, ≥50% increase from the nadir in the sum of products of diameters (SPD) of target lesions, ≥50% increase in the LD of an individual node or extra-nodal mass, splenic/hepatic enlargement of ≥50% from nadir, unequivocal increase in the size of non-target disease, transformation to a more aggressive histology, decrease in platelet count or Hgb, \>50% decrease from the highest on-study platelet count, \>20 grams per Liter (g/L) decrease from the highest on-study hemoglobin (Hgb).
Time frame: From enrolment to the earlier of the first documentation of definitive disease progression (PD) or death (Up to 87 months)
Overall Response Rate (ORR) Per iwCLL Criteria
ORR=percent of participants who achieve complete response (CR), complete response with incomplete marrow recovery (CRi), partial response (PR) or nodular partial response (nPR).CR: No evidence of new disease; Absolute lymphocyte count(ALC)\<4x10\^9/liter(L);Regression of all target nodal masses to ≤1.5cm in LD;Normal spleen,liver size;Regression to normal of all nodal non-target disease and disappearance of all detectable;Non-nodal,non-target disease;Morphologically negative bone marrow;No lymphoid nodules;ANC \>1.5x10\^9/L,platelets≥100x10\^9/L,Hgb≥110 g/L.PR:No evidence of new disease; Response in 2 of following if abnormal at baseline: ALC\<4x10\^9/L or ≥50% decrease from baseline in sum of products of target nodal lesions;splenomegaly; hepatomegaly;≥50% decrease from baseline in CLL marrow infiltrate/B-lymphoid nodules;response in any 1: ANC\>1.5x10\^9/L, platelets\>100x10\^9/L,Hgb\>110g/L or ≥50% increase over baseline in any of these.CRi:for CR except with ANC\<1000/µL and/or platelets\<100.
Time frame: Up to 87 months
Complete Response (CR) Rate
The CR rate is defined as the percentage of participants with a best overall response of complete response (CR) or complete response with incomplete marrow recovery (CRi). CR: No evidence of new disease; Absolute lymphocyte count(ALC)\<4x10\^9/L; Regression of all target nodal masses to ≤1.5 cm in LD; Normal spleen,liver size; Regression to normal of all nodal non-target disease and disappearance of all detectable; Non-nodal, non-target disease; Morphologically negative bone marrow; No lymphoid nodules; ANC\>1.5x10\^9/L,platelets≥100x10\^9/L,hemoglobin (Hgb)≥110 g/L. CRi was as for CR except with ANC \<1000/µL and/or platelets \<100,000/µL.
Time frame: Up to 87 months
Minimal Residual Disease (MRD) Negativity Rate
MRD negativity rate is defined as the percentage of participants who are MRD negative. If a participant was determined to be MRD negative by peripheral blood, a bone marrow aspirate was obtained to assess MRD in the bone marrow.
Time frame: From Cycle 6 until Cycle 15 (cycle length=28 days) up to approximately 81.5 months
Duration of Response (DOR)
DOR is defined as the interval from the first documentation of CR, CRi, PR, or nPR to the earlier of the first documentation of definitive disease progression or death from any cause.
Time frame: From first documentation of response to study treatment till disease progression/death (up to approximately 87 months)
Number of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE)
An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product. An AE does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is any AE that occur after first dosing of study medication and through the end of the study or through 30 days after the last dose of study treatment, or is considered treatment-related regardless of the start date of the event, or is present before first dosing of study medication but worsens in intensity or the investigator subsequently considers treatment-related.
Time frame: From first dose of study treatment up to end of study (up to approximately 87 months)
Participants took part in the study at multiple investigative sites in the United States, Israel, Italy, Poland, Russian Federation, Spain and the United Kingdom from 19 November 2015 to 22 February 2023.
| Milestone | Experimental: Arm A: Ublituximab + Umbralisib | Active Comparator: Arm B: Obinutuzumab + Chlorambucil | Experimental: Arm C: Ublituximab | Experimental: Arm D: Umbralisib |
|---|---|---|---|---|
| Started | 210 | 211 | 91 | 91 |
| Safety population | 206 | 200 | 91 | 86 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 210 | 211 | 91 | 91 |
| Withdrew: Adverse event | 16 | 12 | 7 | 13 |
| Withdrew: Death | 29 | 10 | 11 | 11 |
| Withdrew: Initiation of non-protocol intervention | 5 | 3 | 0 | 0 |
| Withdrew: Investigator's decision | 11 | 15 | 6 | 6 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 | 1 |
| Withdrew: Lost to follow-up | 2 | 2 | 1 | 2 |
| Withdrew: Progressive disease confirmed by central radiology | 75 | 113 | 38 | 43 |
| Withdrew: Site terminated by sponsor | 29 | 12 | 13 | 5 |
| Withdrew: Withdrawal by subject of consent or to discontinue treatment | 29 | 24 | 6 | 5 |
| Withdrew: Reason not specified | 3 | 7 | 4 | 5 |
| Withdrew: Unknown/missing | 10 | 13 | 4 | 0 |
| Withdrew: Non-compliance with study | 1 | 0 | 0 | 0 |
PFS was defined as the interval from enrollment to the earlier of the first documentation of definitive disease progression (PD) or death from any cause. PD was appearance of new nodes \>1.5 centimetres (cm) in the longest diameter (LD) and \>1.0 in longest perpendicular diameter (LPD), new or recurrent hepatomegaly or splenomegaly, new or reappearance of an unequivocal extra-nodal lesion, ≥50% increase from the nadir in the sum of products of diameters (SPD) of target lesions, ≥50% increase in the LD of an individual node or extra-nodal mass, splenic/hepatic enlargement of ≥50% from nadir, unequivocal increase in the size of non-target disease, transformation to a more aggressive histology, decrease in platelet count or Hgb, \>50% decrease from the highest on-study platelet count, \>20 grams per Liter (g/L) decrease from the highest on-study hemoglobin (Hgb).
| Months | Experimental: Arm A: Ublituximab + Umbralisib | Active Comparator: Arm B: Obinutuzumab + Chlorambucil | Experimental: Arm C: Ublituximab | Experimental: Arm D: Umbralisib |
|---|---|---|---|---|
| Progression-Free Survival (PFS) Per International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Criteria | 33.2 (27.7 to 39.6) | 17.5 (16.6 to 22.6) | 32.9 (19.1 to 45.0) | 22.4 (17.2 to 34.7) |
ORR=percent of participants who achieve complete response (CR), complete response with incomplete marrow recovery (CRi), partial response (PR) or nodular partial response (nPR).CR: No evidence of new disease; Absolute lymphocyte count(ALC)\<4x10\^9/liter(L);Regression of all target nodal masses to ≤1.5cm in LD;Normal spleen,liver size;Regression to normal of all nodal non-target disease and disappearance of all detectable;Non-nodal,non-target disease;Morphologically negative bone marrow;No lymphoid nodules;ANC \>1.5x10\^9/L,platelets≥100x10\^9/L,Hgb≥110 g/L.PR:No evidence of new disease; Response in 2 of following if abnormal at baseline: ALC\<4x10\^9/L or ≥50% decrease from baseline in sum of products of target nodal lesions;splenomegaly; hepatomegaly;≥50% decrease from baseline in CLL marrow infiltrate/B-lymphoid nodules;response in any 1: ANC\>1.5x10\^9/L, platelets\>100x10\^9/L,Hgb\>110g/L or ≥50% increase over baseline in any of these.CRi:for CR except with ANC\<1000/µL and/or platelets\<100.
| percentage of participants | Experimental: Arm A: Ublituximab + Umbralisib | Active Comparator: Arm B: Obinutuzumab + Chlorambucil | Experimental: Arm C: Ublituximab | Experimental: Arm D: Umbralisib |
|---|---|---|---|---|
| Overall Response Rate (ORR) Per iwCLL Criteria | 83.3 | 68.7 | 42.9 | 61.5 |
The CR rate is defined as the percentage of participants with a best overall response of complete response (CR) or complete response with incomplete marrow recovery (CRi). CR: No evidence of new disease; Absolute lymphocyte count(ALC)\<4x10\^9/L; Regression of all target nodal masses to ≤1.5 cm in LD; Normal spleen,liver size; Regression to normal of all nodal non-target disease and disappearance of all detectable; Non-nodal, non-target disease; Morphologically negative bone marrow; No lymphoid nodules; ANC\>1.5x10\^9/L,platelets≥100x10\^9/L,hemoglobin (Hgb)≥110 g/L. CRi was as for CR except with ANC \<1000/µL and/or platelets \<100,000/µL.
| percentage of participants | Experimental: Arm A: Ublituximab + Umbralisib | Active Comparator: Arm B: Obinutuzumab + Chlorambucil | Experimental: Arm C: Ublituximab | Experimental: Arm D: Umbralisib |
|---|---|---|---|---|
| Complete Response (CR) Rate | 5.7 | 1.4 | 3.3 | 0 |
MRD negativity rate is defined as the percentage of participants who are MRD negative. If a participant was determined to be MRD negative by peripheral blood, a bone marrow aspirate was obtained to assess MRD in the bone marrow.
| percentage of participants | Experimental: Arm A: Ublituximab + Umbralisib | Active Comparator: Arm B: Obinutuzumab + Chlorambucil | Experimental: Arm C: Ublituximab | Experimental: Arm D: Umbralisib |
|---|---|---|---|---|
| Minimal Residual Disease (MRD) Negativity Rate | 29.0 | 34.6 | 36.3 | 5.5 |
DOR is defined as the interval from the first documentation of CR, CRi, PR, or nPR to the earlier of the first documentation of definitive disease progression or death from any cause.
| months | Experimental: Arm A: Ublituximab + Umbralisib | Active Comparator: Arm B: Obinutuzumab + Chlorambucil | Experimental: Arm C: Ublituximab | Experimental: Arm D: Umbralisib |
|---|---|---|---|---|
| Duration of Response (DOR) | 32.9 (27.8 to 39.4) | 21.9 (14.6 to 26.6) | 47.5 (40.3 to 57.8) | 29.3 (17.1 to 36.5) |
An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product. An AE does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is any AE that occur after first dosing of study medication and through the end of the study or through 30 days after the last dose of study treatment, or is considered treatment-related regardless of the start date of the event, or is present before first dosing of study medication but worsens in intensity or the investigator subsequently considers treatment-related.
| Participants | Experimental: Arm A: Ublituximab + Umbralisib | Active Comparator: Arm B: Obinutuzumab + Chlorambucil | Experimental: Arm C: Ublituximab | Experimental: Arm D: Umbralisib |
|---|---|---|---|---|
| Number of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE) | 205 | 195 | 88 | 86 |
Collected over From first dose of study treatment up to end of study (up to approximately 87 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Experimental: Arm A: Ublituximab + Umbralisib | 82/206 (39.8%) | 118/206 (57.3%) | 205/206 (99.5%) |
| Active Comparator: Arm B: Obinutuzumab + Chlorambucil | 40/200 (20%) | 47/200 (23.5%) | 189/200 (94.5%) |
| Experimental: Arm C: Ublituximab | 25/91 (27.5%) | 33/91 (36.3%) | 84/91 (92.3%) |
| Experimental: Arm D: Umbralisib | 29/86 (33.7%) | 34/86 (39.5%) | 84/86 (97.7%) |
| Event | Experimental: Arm A: Ublituximab + Umbralisib | Active Comparator: Arm B: Obinutuzumab + Chlorambucil | Experimental: Arm C: Ublituximab | Experimental: Arm D: Umbralisib |
|---|---|---|---|---|
| PneumoniaInfections and infestations | 21/206 | 4/200 | 4/91 | 0/86 |
| COVID-19 pneumoniaInfections and infestations | 10/206 | 0/200 | 8/91 | 0/86 |
| COVID-19Infections and infestations | 13/206 | 0/200 | 4/91 | 1/86 |
| SepsisInfections and infestations | 7/206 | 1/200 | 4/91 | 2/86 |
| AnaemiaBlood and lymphatic system disorders | 2/206 | 2/200 | 1/91 | 3/86 |
| Urinary tract infectionInfections and infestations | 5/206 | 1/200 | 1/91 | 1/86 |
| Febrile neutropeniaBlood and lymphatic system disorders | 3/206 | 2/200 | 2/91 | 2/86 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/206 | 0/200 | 1/91 | 2/86 |
| DizzinessNervous system disorders | 2/206 | 0/200 | 0/91 | 2/86 |
| Atrial fibrillationCardiac disorders | 3/206 | 0/200 | 2/91 | 0/86 |
| Event | Experimental: Arm A: Ublituximab + Umbralisib | Active Comparator: Arm B: Obinutuzumab + Chlorambucil | Experimental: Arm C: Ublituximab | Experimental: Arm D: Umbralisib |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 118/206 | 45/200 | 24/91 | 54/86 |
| NauseaGastrointestinal disorders | 105/206 | 75/200 | 27/91 | 34/86 |
| Infusion related reactionInjury, poisoning and procedural complications | 92/206 | 49/200 | 36/91 | 0/86 |
| NeutropeniaBlood and lymphatic system disorders | 70/206 | 79/200 | 25/91 | 15/86 |
| FatigueGeneral disorders | 76/206 | 60/200 | 28/91 | 22/86 |
| CoughRespiratory, thoracic and mediastinal disorders | 62/206 | 36/200 | 18/91 | 18/86 |
| ChillsGeneral disorders | 52/206 | 33/200 | 25/91 | 12/86 |
| HeadacheNervous system disorders | 56/206 | 36/200 | 18/91 | 17/86 |
| PyrexiaGeneral disorders | 53/206 | 38/200 | 22/91 | 11/86 |
| Upper respiratory tract infectionInfections and infestations | 48/206 | 26/200 | 16/91 | 18/86 |
The Intent-to-Treat (ITT) population included all randomized participants, regardless of administration of study treatment (ublituximab, TGR-1202, obinutuzumab + chlorambucil, or ublituximab + TGR-1202).
| Age, Continuous(years) | Experimental: Arm A: Ublituximab + Umbralisib | Active Comparator: Arm B: Obinutuzumab + Chlorambucil | Experimental: Arm C: Ublituximab | Experimental: Arm D: Umbralisib | Total |
|---|---|---|---|---|---|
| Mean | 66.2 (39 to 88) | 67.1 (36 to 91) | 67.6 (40 to 88) | 66.3 (43 to 86) | 66.8 (36 to 91) |
| Sex: Female, Male(Participants) | Experimental: Arm A: Ublituximab + Umbralisib | Active Comparator: Arm B: Obinutuzumab + Chlorambucil | Experimental: Arm C: Ublituximab | Experimental: Arm D: Umbralisib | Total |
|---|---|---|---|---|---|
| Female | 75 | 67 | 23 | 30 | 195 |
| Male | 135 | 144 | 68 | 61 | 408 |
| Ethnicity (NIH/OMB)(Participants) | Experimental: Arm A: Ublituximab + Umbralisib | Active Comparator: Arm B: Obinutuzumab + Chlorambucil | Experimental: Arm C: Ublituximab | Experimental: Arm D: Umbralisib | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 5 | 2 | 3 | 13 |
| Not Hispanic or Latino | 193 | 194 | 86 | 83 | 556 |
| Unknown or Not Reported | 14 | 12 | 3 | 5 | 34 |
| Race/Ethnicity, Customized(Participants) | Experimental: Arm A: Ublituximab + Umbralisib | Active Comparator: Arm B: Obinutuzumab + Chlorambucil | Experimental: Arm C: Ublituximab | Experimental: Arm D: Umbralisib | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 0 | 0 | 1 |
| Asian | 0 | 1 | 1 | 1 | 3 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 0 | 1 |
| Black or African American | 9 | 6 | 5 | 5 | 25 |
| White | 189 | 195 | 83 | 82 | 549 |
| Multiple | 2 | 0 | 0 | 0 | 2 |
| Other | 1 | 1 | 0 | 2 | 4 |
| Not Reported | 8 | 7 | 2 | 1 | 18 |
Showing the first 100 of 154 sites across 7 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2015 to primary completion in Feb 2023, 87 months.
Results were first posted in May 2024, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Ublituximab · Umbralisib
Leukemia, Lymphocytic, Chronic, B-Cell →